Association of human epidermal growth factor receptor 2 status with ipsilateral breast tumor recurrence and resistance to endocrine therapy

MAKOTO ISHITOBI, MIZUHO SHIBA, TAKAHIRO NAKAYAMA, HIROKI KOYAMA and YASUHIRO TAMAKI

Department of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Osaka 537-8511, Japan

Received February 6, 2015; Accepted March 20, 2015

DOI: 10.3892/mco.2015.534

Abstract. The effect of prior endocrine therapy on tumor biology and clinical outcomes of locoregional recurrence remains unclear. A total of 76 patients, who underwent salvage breast surgery for estrogen receptor-positive ipsilateral breast tumor recurrence (IBTR) following breast-conserving surgery for primary breast cancer, were retrospectively reviewed to investigate the association of human epidermal growth factor receptor 2 (HER2) status with the characteristics of IBTR and clinical outcomes following resection of IBTR. There was a tendency for more patients with HER2-positive IBTR to show resistance to endocrine therapy (71.4%) compared with those with HER2-negative IBTR (37.3%) (P=0.085). Patients with HER2-positive IBTR exhibited a higher rate of recurrence (62.5%) compared with those with HER2-negative IBTR (25.0%) (P=0.027). These results suggested that HER2-positive IBTR may be associated with resistance to endocrine therapy and a poorer clinical outcome.

Introduction

Breast-conserving surgery is the standard treatment for early breast cancer. However, ~5-10% of the patients treated with breast-conserving surgery subsequently develop ipsilateral breast tumor recurrence (IBTR) within 10 years (1,2). IBTR following breast-conserving treatment is associated with an increased risk of distant disease and mortality (3-6). The available data supporting the recommendation of systemic treatment for breast cancer patients with locoregional recurrence are sparse (7-9), whereas adjuvant systemic therapy reduces the risk of relapse and mortality in primary breast cancer patients (10,11). To the best of our knowledge, there has been only one randomized controlled study assessing whether adjuvant endocrine therapy reduces the rate of recurrence in breast cancer patients with locoregional recurrence; the Swiss Group for Clinical Cancer Research demonstrated that tamoxifen following local treatment significantly improved the disease-free survival (DFS) of breast cancer patients with locoregional recurrence (8). However, patients pretreated with adjuvant tamoxifen were not eligible for that study. Therefore, it is unknown whether endocrine therapy may effectively decrease the incidence of recurrence in breast cancer patients with locoregional recurrence who have received adjuvant endocrine therapy for the primary tumor.

In clinical practice, the estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) statuses were found to be factors essential for guiding therapeutic decision-making regarding endocrine and anti-HER2 therapy. Preclinical studies investigated the crosstalk between ER and HER2 and its effect on resistance to endocrine therapy (12-14). In this study, we aimed to assess the association of the HER2 status of ER-positive IBTR following breast-conserving treatment with prior endocrine therapy and patient outcomes.

Patients and methods

Patient selection. We reviewed the records of 3,793 breast cancer patients who underwent breast-conserving surgery between 1989 and 2013 at the Department of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases (Osaka, Japan). A total of 180 patients (4.7%) developed IBTR as a first event, without evidence of synchronous metastatic disease, and underwent salvage surgery. Following the exclusion of i) patients who received neoadjuvant therapy as part of the initial treatment regimen, ii) patients with non-invasive tumors in IBTR specimens and iii) patients who underwent salvage surgery for IBTR prior to 2000 (due to lack of information regarding HER2 status), there were a total of 116 patients with IBTR for whom information was available regarding ER and HER2. Of these 116 patients, 76 with ER-positive IBTR were finally included in this analysis.

Key words: breast cancer, ipsilateral breast tumor recurrence, endocrine therapy, resistance
<table>
<thead>
<tr>
<th>Characteristics</th>
<th>All (n=76)</th>
<th>HER2-negative (n=68)</th>
<th>HER2-positive (n=8)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at initial diagnosis, years</td>
<td></td>
<td></td>
<td></td>
<td>0.78</td>
</tr>
<tr>
<td>Median (range)</td>
<td>49 (29-81)</td>
<td>49 (30-81)</td>
<td>50 (29-69)</td>
<td></td>
</tr>
<tr>
<td>Adjuvant chemotherapy following primary surgery</td>
<td></td>
<td></td>
<td></td>
<td>0.45</td>
</tr>
<tr>
<td>Yes</td>
<td>20</td>
<td>17</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>56</td>
<td>51</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Adjuvant endocrine therapy following primary surgery</td>
<td></td>
<td></td>
<td></td>
<td>0.43</td>
</tr>
<tr>
<td>Yes</td>
<td>58</td>
<td>51</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>18</td>
<td>17</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Adjuvant trastuzumab following primary surgery</td>
<td></td>
<td></td>
<td></td>
<td>NE</td>
</tr>
<tr>
<td>Yes</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>76</td>
<td>68</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Time interval from initial surgery to IBTR, years</td>
<td></td>
<td></td>
<td></td>
<td>0.12</td>
</tr>
<tr>
<td>Median (range)</td>
<td>6.0 (0.5-20.9)</td>
<td>6.3 (0.5-20.9)</td>
<td>5.4 (2.7-11.3)</td>
<td></td>
</tr>
<tr>
<td>Age at IBTR, years</td>
<td></td>
<td></td>
<td></td>
<td>0.62</td>
</tr>
<tr>
<td>Median (range)</td>
<td>57 (36-84)</td>
<td>57 (36-84)</td>
<td>56.5 (38-72)</td>
<td></td>
</tr>
<tr>
<td>pT stage of recurrent breast tumor</td>
<td></td>
<td></td>
<td></td>
<td>0.30</td>
</tr>
<tr>
<td>1</td>
<td>57</td>
<td>52</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>17</td>
<td>14</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Grade of recurrent breast tumor</td>
<td></td>
<td></td>
<td></td>
<td>0.20</td>
</tr>
<tr>
<td>1</td>
<td>17</td>
<td>17</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>34</td>
<td>29</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>16</td>
<td>13</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>9</td>
<td>9</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Lymphovascular invasion of recurrent breast tumor</td>
<td></td>
<td></td>
<td></td>
<td>0.024</td>
</tr>
<tr>
<td>Negative</td>
<td>56</td>
<td>52</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>14</td>
<td>10</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>6</td>
<td>6</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Histological type of recurrent breast tumor</td>
<td></td>
<td></td>
<td></td>
<td>0.70</td>
</tr>
<tr>
<td>Invasive ductal</td>
<td>66</td>
<td>59</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Invasive lobular</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>4</td>
<td>4</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>4</td>
<td>3</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Adjuvant chemotherapy following salvage surgery</td>
<td></td>
<td></td>
<td></td>
<td>0.058</td>
</tr>
<tr>
<td>Yes</td>
<td>6</td>
<td>4</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>70</td>
<td>64</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Adjuvant endocrine therapy following salvage surgery</td>
<td></td>
<td></td>
<td></td>
<td>0.34</td>
</tr>
<tr>
<td>Yes</td>
<td>69</td>
<td>61</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>7</td>
<td>7</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Adjuvant trastuzumab following salvage surgery</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Yes</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>73</td>
<td>68</td>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>
This study was approved by the local Ethics Committee of
Osaka Medical Center of Cancer and Cardiovascular Diseases.

**Hormone receptor status.** The patients received a physical
examination every 3-6 months for the first 5 years following
primary and salvage surgery and annually thereafter.
Mammograms were performed annually following primary
and salvage surgery. The ER status was determined by
immunohistochemistry and tumors with ≥10% positively
stained cells were classified as positive. The HER2 status
was considered as positive if immunohistochemistry was 3+
or if the fluorescence in situ hybridization amplification score
(HER2/neu to chromosome 17 ratio) was >2.0.

**Definition of resistance.** Resistance to endocrine therapy
was defined as disease relapse while receiving adjuvant endocrine
therapy, or relapse within 12 months of completing such
therapy (15). The absence of resistance to endocrine therapy
was defined as relapse after 12 months of completing adjuvant
endocrine therapy.

**Statistical analysis.** The association of the HER2 status
with various clinical or pathological factors of IBTR was assessed
using the Student's t-test or the Chi-square test. DFS was
defined as the period from the date of surgery for IBTR to the
date of appearance of any recurrence and was calculated by the
Kaplan-Meier method. The log-rank test was used to evaluate
differences in DFS among various patient subgroups. All
the statistical tests and P-values were two-tailed and P<0.05 was
considered to indicate a statistically significant difference. All
the statistical analyses were performed with SPSS statistical
software, version 21 (IBM Japan, Ltd., Tokyo, Japan).

**Results**

**Patient characteristics and association with HER2 status.**
The patient characteristics according to the HER2 status are
shown in Table I. With respect to clinicopathological factors,
there were no significant differences between patients with
HER2-positive and those with HER2-negative IBTR, except
in patients with lymphovascular invasion (P=0.024).

Of the 76 patients, 58 (76.3%) received adjuvant endocrine
therapy following primary surgery. Among these 58 patients,
there was a non-significant tendency for more patients with
HER2-positive IBTR to show resistance to endocrine therapy
(71.4%, 5/7) compared with those with HER2-negative IBTR
(37.3%, 19/51) (P=0.085 by Chi-square test; data not shown).

**Follow-up.** Within a median follow-up period of 2.4 years
(range, 0.1-11.6 years), 22 of the 76 patients (28.9%) experi-
enced disease recurrence. Patients with HER2-positive IBTR
exhibited a higher rate of recurrence (62.5%) compared
with those with HER2-negative IBTR (25.0%) (Chi-square
P=0.027; Table I). The 3-year DFS rates in patients with
HER2-positive and -negative IBTR were 50.0 and 77.0%,
respectively (log-rank test P=0.34; data not shown).

**Discussion**

In this study, the presence of resistance to endocrine therapy
was associated with a higher frequency of HER2-positive
IBTR. Moreover, patients with HER2-positive IBTR exhib-
itd a higher rate of recurrence compared with those with
HER2-negative IBTR. Our analysis was limited to patients
with ER-positive IBTR who were candidates for endocrine
therapy following IBTR resection. There is limited available
evidence regarding the effect of adjuvant endocrine therapy
on decreasing recurrence in patients with IBTR following its
resection. Our findings may provide a new insight regarding
the mechanisms of resistance to endocrine therapy.

Several preclinical studies have investigated the crosstalk
between ER and HER2 and the effect of the HER2 status on
resistance to endocrine therapy (12-14). Massarweh et al (14)
reported that acquired tamoxifen resistance in MCF-7 tumors
was associated with increased HER2 expression, which was
consistent with our clinical data. Until recently, the available
clinical data on the association between biomarker changes
and resistance to endocrine therapy have been limited.
Arnedos et al (16) investigated biomarker changes associated
with the development of resistance to aromatase inhibitors in
ER-positive breast cancer. The authors of that study evaluated
biomarker changes using pairs of samples from patients who
had relapsed or progressed while receiving aromatase inhibi-
tors and found that there were no marked changes in the HER2
status; however, in a small proportion of tumors (5.6%, 3/54),
HER2 was positive in recurrent tumors, despite the primary
tumors being HER2-negative.

Several studies reported on the association between prior
systemic therapy and the characteristics of subsequently de-
veloping tumors, including contralateral breast cancer (17) or any
site of recurrence (18). Swain et al (17) reported that patients
with ER-positive primary cancer who received tamoxifen had
fewer ER-positive contralateral breast cancers compared with
those who did not receive tamoxifen, which may be a result
of tamoxifen treatment. In that study, analyses of the HER2
status were not performed. Niikura et al (18) evaluated the HER2 status of metastatic sites in patients with HER2-positive primary tumors and found that HER2-negative metastatic tumors were more frequent among patients who had received chemotherapy compared with those who had not. Prior trastuzumab did not affect the HER2 status of metastatic tumors. The results suggested that the increased rate of HER2-negative metastatic tumors following chemotherapy may be associated with biopsies sampling HER2-negative subclones.

Our study had several limitations, including the small sample size, short follow-up period, retrospective nature of the study design and lack of information regarding primary tumors. In addition, as the majority of the patients in our study received treatment for primary tumors in the pre-trastuzumab era, the effect of prior trastuzumab on the breast cancer subtype of the recurrent tumors is unknown.

In conclusion, the HER2 status of IBTR was found to be associated with resistance to endocrine therapy and a poorer clinical outcome. However, further investigation is required to elucidate the mechanisms of resistance to endocrine therapy.

Acknowledgements

This study was supported in part by the Osaka Foundation for the Prevention of Cancer and Cardiovascular Diseases.

References